Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
For the symptomatic treatment of tinnitus, vertigo and visual field disturbances, the EU health authority concluded that the benefits no longer outweigh the risks and that these uses should no longer be authorized.